Compare Inovio Pharmaceuticals Inc (INO) vs ProShares UltraShort Bloomberg Natural Gas ETF (KOLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs ProShares UltraShort Bloomberg Natural Gas ETF — how do they compare? Inovio Pharmaceuticals Inc trades at $1.1 (market cap $112.19M), while ProShares UltraShort Bloomberg Natural Gas ETF trades at $24.45 (market cap $141.25M). The key difference: ProShares UltraShort Bloomberg Natural Gas ETF is the larger of the two by market cap, and ProShares UltraShort Bloomberg Natural Gas ETF is more actively traded (5,492,367 versus 3,201,278). Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and ProShares UltraShort Bloomberg Natural Gas ETF for 10 Days on average.
| INO | KOLD | |
|---|---|---|
Market Cap | $112.19M | $141.25M |
Volume | 3,201,278 | 5,492,367 |
Sector | Health | Leveraged / Inverse |
52-Week High | $2.65 | $49.39 |
52-Week Low | $0.66 | $13.58 |
Typical Hold Time | 43 Days | 10 Days |
Enterprise Value | $83.51M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals (INO) trades at $1.09, down 5.63% today, reflecting ongoing financial challenges with minimal revenue of $65,340 in 2025 and substantial losses. The company shows consistent negative cash flow from operations but has beaten EPS estimates in recent quarters. Technical indicators are bearish, with moving averages and oscillators signaling selling pressure. Key near-term catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, its lead candidate for recurrent respiratory papillomatosis.
The investment case hinges on FDA approval of INO-3107, with analyst consensus target at $2.75 offering significant upside. However, high burn rate, negative margins, and dependence on financing pose substantial risks. Positive regulatory outcome could drive revaluation, but failure may exacerbate financial strain. Wall Street maintains cautious optimism with 59% buy ratings.
KOLD is trading at $24.52, down 1.29% over the past day, with a bearish technical signal driven by moving averages. The stock lacks key financial ratio data, and recent news highlights volatility in natural gas markets, with record-high U.S. production and geopolitical tensions influencing sentiment.
The outlook for KOLD is clouded by weak technicals and fundamental data gaps. Investment opportunities are limited without clear earnings or valuation metrics, while risks include energy market volatility and competitive pressures from high natural gas supply.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About ProShares UltraShort Bloomberg Natural Gas ETF
KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.
Read more on KOLD →
